ASweetLife Team, Author at ASweetLife

FDA Approves t:connect Diabetes Management Application for Use With Tandem’s t:slim Insulin Pump

The U.S. FDA cleared Tandem's t:connect Diabetes Management Application, the web-based data management companion to the t:slim Insulin Pump. The t:connect Application is a Mac and PC-compatible data management software application that provides t:slim pump users and their healthcare providers a fast, easy, and visual way to display data from the pump and supported blood glucose meters.

FDA to Review NDA for Lixisenatide, Sanofi’s New Type 2 Diabetes Therapy

The FDA has accepted Sanofi's New Drug Application (NDA) for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes, for review. The acceptance of the lixisenatide NDA filing follows the February 1, 2013, European Commission approval of lixisenatide in the European Union.

Novo Nordisk Recognizes Type 2 Diabetes Patients Who Give Back

Sponsored Content: Novo Nordisk, a world leader in diabetes care, today kicked off the first NovoLog® Community Star contest. As part of the program, type 2 diabetes patients successfully managing their blood sugar with NovoLog® (insulin aspart [rDNA origin] injection)

FDA Delays Review of Novo Nordisk’s New Drug Applications for Tresiba and Ryzodeg

The U.S. FDA issued a Complete Response Letter regarding the New Drug Applications for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) informing Novo Nordisk that an application cannot be approved in its current form.

Lyxumia, Sanofi’s Type 2 Diabetes Treatment, Approved in EU

The European Commission has granted Marketing Authorisation in Europe for Sanofi's new type 2 diabetes treatment, Lyxumia (lixisenatide). Lyxumia is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of patients with type 2 diabetes mellitus. GLP-1 is a naturally-occurring peptide hormone that is released within minutes after eating a meal.

Diamyd to Launch New Clinical Study of Diabetes Vaccine in Children

Diamyd Medical is planning to launch a new clinical study with its diabetes vaccine, Diamyd, during February 2013. The study, approved by the Swedish Medical Products Agency, combines the diabetes vaccine Diamyd with relatively high doses of vitamin D and the anti-inflammatory drug ibuprofen. The purpose of the treatment is to preserve the body's own ability to control the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.

Takeda’s Three New Type 2 Diabetes Therapies Approved by FDA

Takeda Pharmaceutical has received FDA approval for three new treatments for type 2 diabetes - NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl).

Novo Nordisk’s New Insulins, Tresiba and Ryzodeg, Approved by EU

The European Commission has granted Novo Nordisk marketing authorizations for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults in 27 European Union member states.

Support the Production of Sugar Babies

Sugar Babies examines the public heath epidemic of diabetic children in America. Both type 1 and type 2 diabetes are on the rise and threaten to become a healthcare crisis in the next decade.

Diabetes Research Breakthrough: How Insulin Binds

For more than 20 years scientists have been trying to solve the mystery of how insulin binds to the insulin receptor, a discovery which could help improve treatments for both patients with type 1 and type diabetes. It seems that a research team at the Walter and Eliza Hall Institute in Melbourne, Australia, led by Associate Professor Mike Lawrence, Dr Colin Ward and Dr John Menting have now found the answer.